首页 > 最新文献

Australian Prescriber最新文献

英文 中文
Inhaler device selection for people with asthma or chronic obstructive pulmonary disease. 为哮喘或慢性阻塞性肺病患者选择吸入器。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.046
Deborah Rigby

There are many types of inhaler device, each with its own characteristics, benefits and limitations. Inhaler device selection should be individualised. Assessment of the patient's inspiratory flow, dexterity, coordination and preferences can help guide selection of a device that the patient can and will use effectively. For patients who require multiple inhaled drugs, prescribing combination inhalers and avoiding the use of more than one type of inhaler device can reduce errors in inhaler technique and improve adherence. Inhaler technique and adherence should be regularly reviewed. Environmental impact of inhalers can be reduced by optimising symptom control to minimise the need for short-acting beta2 agonists, and choosing inhalers with a low carbon footprint.

吸入器有很多种，每种都有自己的特点、优点和局限性。吸入器装置的选择应因人而异。对患者的吸气流量、灵活性、协调性和偏好进行评估，有助于指导选择患者能够并愿意有效使用的装置。对于需要多种吸入药物的患者，开具联合吸入器处方并避免使用一种以上的吸入器装置可减少吸入器使用技巧的错误并提高依从性。应定期检查吸入器技术和依从性。通过优化症状控制以尽量减少对短效 β2受体激动剂的需求，以及选择低碳足迹的吸入器，可以减少吸入器对环境的影响。
{"title":"Inhaler device selection for people with asthma or chronic obstructive pulmonary disease.","authors":"Deborah Rigby","doi":"10.18773/austprescr.2024.046","DOIUrl":"https://doi.org/10.18773/austprescr.2024.046","url":null,"abstract":"<p><p>There are many types of inhaler device, each with its own characteristics, benefits and limitations. Inhaler device selection should be individualised. Assessment of the patient's inspiratory flow, dexterity, coordination and preferences can help guide selection of a device that the patient can and will use effectively. For patients who require multiple inhaled drugs, prescribing combination inhalers and avoiding the use of more than one type of inhaler device can reduce errors in inhaler technique and improve adherence. Inhaler technique and adherence should be regularly reviewed. Environmental impact of inhalers can be reduced by optimising symptom control to minimise the need for short-acting beta<sub>2</sub> agonists, and choosing inhalers with a low carbon footprint.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"140-147"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valediction: Ruth Sutherland. 致辞露丝-萨瑟兰
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.043
{"title":"Valediction: Ruth Sutherland.","authors":"","doi":"10.18773/austprescr.2024.043","DOIUrl":"https://doi.org/10.18773/austprescr.2024.043","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"156"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis. 阿伐潘治疗抗中性粒细胞胞浆抗体相关性血管炎。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.038
{"title":"Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis.","authors":"","doi":"10.18773/austprescr.2024.038","DOIUrl":"https://doi.org/10.18773/austprescr.2024.038","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"158-159"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fezolinetant for moderate to severe vasomotor symptoms associated with menopause. Fezolinetant 用于治疗与更年期有关的中度至重度血管运动症状。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.042
{"title":"Fezolinetant for moderate to severe vasomotor symptoms associated with menopause.","authors":"","doi":"10.18773/austprescr.2024.042","DOIUrl":"https://doi.org/10.18773/austprescr.2024.042","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"162-163"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reflections on community antimicrobial use in Australia. 对澳大利亚社区抗菌药使用情况的思考。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.047
John Turnidge, Carolyn Hullick, Kim Stewart
{"title":"Reflections on community antimicrobial use in Australia.","authors":"John Turnidge, Carolyn Hullick, Kim Stewart","doi":"10.18773/austprescr.2024.047","DOIUrl":"https://doi.org/10.18773/austprescr.2024.047","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"138-139"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune checkpoint inhibitors and immune-related adverse events. 免疫检查点抑制剂与免疫相关不良事件。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.039
Winston Naidoo, Katharine Cuff, Marissa Ryan
{"title":"Immune checkpoint inhibitors and immune-related adverse events.","authors":"Winston Naidoo, Katharine Cuff, Marissa Ryan","doi":"10.18773/austprescr.2024.039","DOIUrl":"https://doi.org/10.18773/austprescr.2024.039","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"153-155"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clascoterone for acne. 治疗痤疮的 Clascoterone
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.040
{"title":"Clascoterone for acne.","authors":"","doi":"10.18773/austprescr.2024.040","DOIUrl":"https://doi.org/10.18773/austprescr.2024.040","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"160-161"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prasterone for vulvar and vaginal atrophy in postmenopausal women. 普拉雄酮治疗绝经后妇女的外阴和阴道萎缩。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.041
{"title":"Prasterone for vulvar and vaginal atrophy in postmenopausal women.","authors":"","doi":"10.18773/austprescr.2024.041","DOIUrl":"https://doi.org/10.18773/austprescr.2024.041","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"164"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mineralocorticoid receptor antagonists in adults with resistant hypertension and obstructive sleep apnoea. 矿物质皮质激素受体拮抗剂在成人耐药性高血压和阻塞性睡眠呼吸暂停患者中的应用。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.033
{"title":"Mineralocorticoid receptor antagonists in adults with resistant hypertension and obstructive sleep apnoea.","authors":"","doi":"10.18773/austprescr.2024.033","DOIUrl":"10.18773/austprescr.2024.033","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"129-130"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological management of polycystic ovary syndrome. 多囊卵巢综合征的药物治疗。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.030
Carolyn Ee, Chau Thien Tay

Polycystic ovary syndrome is a common and frequently undiagnosed female endocrine disorder that is associated with diverse symptoms and features, and an increased risk of long-term chronic diseases such as type 2 diabetes and cardiovascular disease. Pharmacotherapy for polycystic ovary syndrome should be directed at the key concerns of the individual patient. The combined oral contraceptive pill or metformin may be prescribed for irregular periods. The combined oral contraceptive pill is preferred over antiandrogens for treatment of hirsutism and acne. Metformin is of benefit for reducing excess body weight and improving hormonal and metabolic outcomes in those with high metabolic risk (e.g. body mass index greater than 25 kg/m2). Inositol appears to have limited benefits for metabolic outcomes, although it is associated with fewer adverse effects than metformin. Modification of lifestyle factors is important as part of a holistic approach to managing polycystic ovary syndrome. Anti-obesity drugs may be considered for weight management in addition to lifestyle interventions.

多囊卵巢综合征是一种常见的女性内分泌失调症，也是一种经常未确诊的疾病，具有多种症状和特征，并增加了罹患 2 型糖尿病和心血管疾病等长期慢性疾病的风险。多囊卵巢综合征的药物治疗应针对患者的主要关切。月经不调患者可服用复方口服避孕药或二甲双胍。在治疗多毛症和痤疮时，复方口服避孕药优于抗雄激素。二甲双胍可减轻高代谢风险人群（如体重指数大于 25 kg/m2）的过重体重，改善荷尔蒙和新陈代谢状况。肌醇对代谢结果的益处似乎有限，但其不良反应比二甲双胍少。作为多囊卵巢综合征综合治疗方法的一部分，改变生活方式非常重要。除生活方式干预外，还可考虑使用抗肥胖药物来控制体重。
{"title":"Pharmacological management of polycystic ovary syndrome.","authors":"Carolyn Ee, Chau Thien Tay","doi":"10.18773/austprescr.2024.030","DOIUrl":"10.18773/austprescr.2024.030","url":null,"abstract":"<p><p>Polycystic ovary syndrome is a common and frequently undiagnosed female endocrine disorder that is associated with diverse symptoms and features, and an increased risk of long-term chronic diseases such as type 2 diabetes and cardiovascular disease. Pharmacotherapy for polycystic ovary syndrome should be directed at the key concerns of the individual patient. The combined oral contraceptive pill or metformin may be prescribed for irregular periods. The combined oral contraceptive pill is preferred over antiandrogens for treatment of hirsutism and acne. Metformin is of benefit for reducing excess body weight and improving hormonal and metabolic outcomes in those with high metabolic risk (e.g. body mass index greater than 25 kg/m<sup>2</sup>). Inositol appears to have limited benefits for metabolic outcomes, although it is associated with fewer adverse effects than metformin. Modification of lifestyle factors is important as part of a holistic approach to managing polycystic ovary syndrome. Anti-obesity drugs may be considered for weight management in addition to lifestyle interventions.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"109-112"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Australian Prescriber
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1